Home > Products > CD3 & PD1
> Human Anti-CD3 x Anti-PD1 Bispecific Antibody (IgG-IgG)
Human Anti-CD3 x Anti-PD1 Bispecific Antibody (IgG-IgG) (CAT#: BSIG-H272)
Anti-CD3 x Anti-PD1 Bispecific Antibody (IgG-IgG) is designed to be generated by crosslinking two full length IgGs, anti-CD3 and anti-PD1 parental antibodies. A stable linkage is formed between the two antibodies. This BsAb can retarget T cells to tumor cells. It is designed for the research of Esophageal cancer; Hodgkin lymphoma; Renal cell cancer (RCC); Mesothelioma; Head and neck squamous cell cancer (HNSCC); Anal cancer; Gastric cancer; Hepatocellular cancer; Nasopharyngeal cancer; Non-small cell lung cancer (NSCLC); Solid tumors therapy.
There are currently no customer reviews or questions for Human Anti-CD3 x Anti-PD1 Bispecific Antibody (IgG-IgG) (BSIG-H272). Click the button below to contact us or submit your feedback about this product.